Skip to main content
About
Company Overview
Corporate Policies
Governance Policies
Team
Partners
Careers
Research
Clinical Trials
Publications
Pipeline
Investors
Newsroom
Contact
Facebook
Twitter
Linkedin
MENU
Home
About
Company Overview
Team
Partners
Careers
Patient Resource
Pipeline
Investors
Newsroom
Contact
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Press Releases
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2022
2021
2020
2019
2018
2017
2016
11/29/2022
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003
11/18/2022
Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission
10/27/2022
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean
10/11/2022
Tetra and Prepaire Jointly Apply to BARDA for Funding
09/08/2022
Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean
09/06/2022
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients
08/11/2022
Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean
08/10/2022
Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections
07/12/2022
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
06/06/2022
Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update
05/31/2022
Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting
05/30/2022
Tetra Bio-Pharma Appoints Chief Financial Officer
05/18/2022
Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD
05/17/2022
Tetra Bio-Pharma Announces Closing of First Tranche with Cannvalate
05/10/2022
Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology
05/05/2022
Tetra Bio-Pharma and Cannvalate Enter Into Partnership
03/17/2022
Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA
03/08/2022
Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD
02/28/2022
Tetra Bio-Pharma Provides Management Update
02/22/2022
Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement
02/16/2022
Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec
02/16/2022
Tetra Bio-Pharma reçoit un appui financier de 4,5 M$ du ministère de l'Économie et de l'Innovation/Investissement Québec
02/14/2022
Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna